Home › Compare › TOIPF vs ABBV
TOIPF yields 2.46% · ABBV yields 3.06%● Live data
📍 TOIPF pulled ahead of the other in Year 3
Combined, TOIPF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of TOIPF + ABBV for your $10,000?
Thai Oil Public Company Limited, together with its subsidiaries, engages in the oil refining and distribution, petrochemicals, lube base oil, and other businesses in Thailand and internationally. It operates through Oil Refinery, Lube Base Oil Refinery, Petrochemical, Power Generation, Marine Transportation Services, Solvent, Ethanol, and Others segments. The company produces gasoline, diesel/gas oil, jet fuel, kerosene, fuel oil, and liquefied petroleum gas; and petrochemical products, such as paraxylene, benzene, toluene, and mixed xylenes. It also produces and distributes lube base oil, bitumen/asphalt, and other by-products, as well as special products, such as treated distillate aromatics extract and slack wax; and hydrocarbon and chemical solvents, and other chemicals. In addition, the company operates natural gas-fired combined-cycle co-generation power plants that generate and sell electricity, steam, and utilities to industrial users, as well as invests in other power generating companies and related business. Further, it is involved in the marine transportation of petroleum, petrochemical, and liquid chemical products; production of ethanol; provision of marine transportation services for crew and utilities; and biogas power generation and distribution. Additionally, the company provides human resource management services; and manufactures and sells linear alkyl benzene and related products. Thai Oil Public Company Limited was founded in 1961 and is headquartered in Bangkok, Thailand.
Full TOIPF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.